Biotech/life sciences PE v HF
Would like to get some insight on career progression, risks/benefits of PE vs. HF in the biotech/life sciences space.
For context, did a few years in consulting, now wrapping up my PhD and am interviewing for life sciences PE and HF/public equities roles.
My sense is that for biotech PE (eg Bain, EQT), the work is mostly large structured financings for biotech and pharma. Comp is backended based on carry. Great career stability, especially at MF where fundraising is constant. Not sure how much the PE brand/prestige matters in this industry.
For the public/HF side (Perceptive, Baker, RTW), it sounds more like individual-focused work and analyses, less so deal making or project managing. Potentially more meritocratic environment/less internal politics? I believe comp upside is greater but so is career risk.
Would love to get some thoughts. Comp-wise HF seems higher than the PE offer (although that could equalize or flip in 4-5 years when carry vests, assuming I stay that long). For career optionality, I’m not so sure which one provides the better skill/network development.
Based on the most helpful WSO content regarding career progression, risks, and benefits of PE vs. HF in the biotech/life sciences space, here's a comprehensive breakdown to guide your decision-making process:
Biotech/Life Sciences Private Equity (PE): - Career Progression: Typically structured with a clear hierarchy. Starting from Analyst/Associate to potentially reaching Partner level. The progression is often slower due to the long-term nature of investments and the necessity for significant experience and a strong network within the biotech/pharma industry. - Risks/Benefits: The main benefit is career stability, especially in larger firms (e.g., Bain, EQT) where constant fundraising provides job security. The work involves large structured financings, offering a deep dive into the operational and financial aspects of biotech and pharma companies. Compensation is usually back-ended, heavily reliant on carry, which could be substantial but takes time to materialize. The prestige of the PE firm can be a significant factor in career opportunities within the industry. - Skill/Network Development: Offers extensive exposure to deal-making, due diligence, and portfolio management, fostering a strong understanding of the operational and financial intricacies of biotech companies. Networking opportunities are vast, especially with industry executives and investment professionals.
Biotech/Life Sciences Hedge Funds (HF): - Career Progression: More meritocratic, with progression largely based on individual performance and the success of your investment picks. The environment can be more volatile, with higher turnover rates compared to PE. - Risks/Benefits: The main benefit is the potential for higher immediate compensation compared to PE, with bonuses reflecting individual and fund performance. The work is more focused on individual analysis and investment decisions rather than deal-making. This can offer a faster-paced environment with more immediate feedback on investment choices. However, career risk is higher due to the performance-based nature of the role. - Skill/Network Development: Focuses on developing strong analytical skills, market understanding, and the ability to make quick, informed decisions. Networking is more focused on the investment community, including other fund managers, analysts, and traders.
Conclusion: - If you value stability, structured career progression, and are interested in the operational side of biotech companies, PE might be more suitable. - If you prefer a faster-paced environment with higher immediate compensation potential and enjoy market analysis and investment decision-making, HF could be a better fit.
Ultimately, both paths offer valuable experiences and opportunities in the biotech/life sciences sector. Consider your career goals, risk tolerance, and the type of work that excites you most when making your decision.
Sources: Why The Grass Isn't Greener: The Private Equity Associate Crisis (PEAC), Any career regrets after moving from PE to public markets?, Why Banking Over Private Equity/Hedge Fund?, IB vs PE vs VC : The rundown, Career Ladder: Equity Research vs. Investment Banking - (A Definitive Guide, Part 3)
Nihil beatae harum mollitia recusandae dolorem. Est fuga minima et est voluptatum nisi. Deserunt libero quibusdam deserunt minus sapiente in unde.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...
Architecto qui nemo assumenda. Nisi animi assumenda iure enim. Sapiente eligendi in velit asperiores et. Dolores consequatur consectetur repudiandae eius sit tempore doloremque. Aspernatur enim aliquid rerum dolores. Quaerat nam ut qui.
Tempore dolores laborum hic tenetur laboriosam. Non et esse necessitatibus deserunt et. Aspernatur tenetur eligendi sunt consequatur.
Quia dolorem et provident quam officia sit et. Veniam in suscipit sit quisquam. Repellat totam minus atque consequatur velit. Cumque officiis qui sit sequi.